US Oncology Pharmaceutical Services, LLC (CIK: 0001311339) EDGAR, Information, Filings... CompaniesBIO.Com

US Oncology Pharmaceutical Services, LLC

Mailing address
C/O US ONCOLOGY, INC., 16825 NORTHCHASE DRIVE, SUITE 1300, HOUSTON, Delaware, 77060
Phone
832-601-8766
State location
Texas
State of incorporation
Delaware
Fiscal year end
December 31
SIC
8093 - (CF Office: Office of Life Sciences) SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC
Filings
N/A

US Oncology Pharmaceutical Services, LLC (CIK: 0001311339) is an American company incorporated in the state of Texas. Head office is located at C/O US ONCOLOGY, INC., 16825 NORTHCHASE DRIVE, SUITE 1300, HOUSTON, Texas, 77060. Work in the industry 8093 - (CF Office: Office of Life Sciences) SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC. US Oncology Pharmaceutical Services, LLC is a public company and trade via Over-The-Counter (OTC).

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by US Oncology Pharmaceutical Services, LLC

Filings	Format	Description	Filed/Effective	File/Film Number
EFFECT	Document	Acc-no: 9999999995-10-000134 (33 Act) Size: KB	Jan-07-2010	333-162514-13 10516043
POS AM	Document	Post-effective amendment to a registration statement that is not immediately effective upon filing Acc-no: 0001193125-09-259422 (33 Act) Size: KB	Dec-23-2009	333-162514-13 091258900
UPLOAD	Document	Acc-no: 0000000000-09-069989 ( Act) Size: KB	Dec-11-2009
AW	Document	Withdrawal of amendment to a registration statement filed under the Securities Act Acc-no: 0001193125-09-249216 (NE Act) Size: KB	Dec-08-2009	333-162514-13 091228579
POS AM	Document	Post-effective amendment to a registration statement that is not immediately effective upon filing Acc-no: 0001193125-09-248624 (33 Act) Size: KB	Dec-08-2009	333-162514-13 091227098
S-4/A	Document	Amendment to Registration of securities issued in business combination transactions Acc-no: 0001193125-09-248515 (33 Act) Size: KB	Dec-07-2009	333-162514-13 091226606
EFFECT	Document	Acc-no: 9999999995-09-003027 (33 Act) Size: KB	Nov-03-2009	333-162514-13 091156132
S-4/A	Document	Amendment to Registration of securities issued in business combination transactions Acc-no: 0001193125-09-213715 (33 Act) Size: KB	Oct-26-2009	333-162514-13 091136786
S-4	Document	Registration of securities issued in business combination transactions Acc-no: 0001193125-09-208587 (33 Act) Size: KB	Oct-15-2009	333-162514-13 091122029
424B3	Document	Prospectus filed pursuant to Rule 424(b)(3) Acc-no: 0001047469-05-006794 (33 Act) Size: KB	Mar-16-2005	333-121410-13 05686184
S-4/A	Document	Amendment to Registration of securities issued in business combination transactions Acc-no: 0001047469-05-006677 (33 Act) Size: KB	Mar-16-2005	333-121410-13 05684173
S-4/A	Document	Amendment to Registration of securities issued in business combination transactions Acc-no: 0001047469-05-006294 (33 Act) Size: KB	Mar-14-2005	333-121410-13 05677108
S-4	Document	Registration of securities issued in business combination transactions Acc-no: 0001047469-04-037612 (33 Act) Size: KB	Dec-17-2004	333-121410-13 041211855

Recent 20 filings. View all US Oncology Pharmaceutical Services, LLC filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

US Oncology Pharmaceutical Services, LLC overview
US Oncology Pharmaceutical Services, LLC job
US Oncology Pharmaceutical Services, LLC stock
US Oncology Pharmaceutical Services, LLC ownership
US Oncology Pharmaceutical Services, LLC CEO
US Oncology Pharmaceutical Services, LLC documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.